Key result
Serum pro-BNP levels were significantly higher in heart transplant patients with acute rejection compared to those without rejection (4843.20 vs 496.30 pg/ml, p=0.001), and levels increased with advanced rejection grades.
Why the study?
Cardiac transplantation is the gold standard for end-stage heart failure, but acute rejection remains the most important factor affecting its success.
Are elevated serum pro-BNP levels and non-invasive parameters associated with acute rejection in patients who undergo cardiac transplantation?
Comparison
Patients with acute rejection (n: 10) vs without rejection (n: 10)
Design
Single-center observational study
Authors
Loading...
Should not yet alter rejection surveillance in heart transplant recipients; leaves open pro-BNP's role in future protocols.
Observational (n=20)
No
Are elevated serum pro-BNP levels and non-invasive parameters associated with acute rejection in patients who undergo cardiac transplantation?
Absolute Event Rate: 4843.2% vs 496.3%
p-value: p=0.001
Serum pro-BNP levels are significantly elevated in cardiac transplant recipients experiencing acute rejection and correlate with the severity of rejection, suggesting its potential utility as an adjunctive non-invasive biomarker.
Özgür Akkaya (2021) conducted an observational in Heart Transplantation (Acute Rejection) (n=20). Acute rejection vs. No rejection was evaluated on Serum pro-BNP levels (pg/ml) (p=0.001). Serum pro-BNP levels were significantly higher in heart transplant patients with acute rejection compared to those without rejection (4843.20 vs 496.30 pg/ml, p=0.001), and levels increased with advanced rejection grades.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: